Lupin Pharmaceuticals Inc. Announces a Nationwide Recall of Mibelas™ 24 Fe (Norethindrone Acetate and EthinylEstradiol 1mg/0.02mg Chewable Tablets and Ferrous Fumarate 75 mg) Tablets Due to Out of Sequence Tablets and Missing Expiry/Lot Information

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

 

05/29/2017 10:22 AM EDT

Baltimore, Maryland, Lupin Pharmaceuticals Inc. announced today that it has voluntarily recalled lot L600518, Exp 05/18 of Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol 1 mg/0.02 mg chewable and ferrous fumarate 75 mg) Tablets at the consumer level. A confirmed market compliant indicated a packaging error, where the blister was rotated 180 degrees within the wallet, reversing the weekly tablet orientation and making the lot number and expiration date no longer visible. The first four days of therapy would have had four non-hormonal placebo tablets as opposed to the active tablets.

For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.


This email was sent to bsamad2007.adnan@blogger.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332) Powered by GovDelivery

Comments

Popular Posts

January 3nd Nоte (Оpen Up)

Reduced Payment!.

We have Your e-Wallet ready. Claim in 3hrs

Your order requires immediate confirmation.

Beneficiary countersignature modification

You’re four weeks away from more followers 📱

The State Department requires proof that you are the owner.

Commissions Successfully

Fwd: Claim "Climate law & governance" for your profile